1. Sulfonylurea agonists, as the name implies, rely on stimulating the body’s remaining normal islet cells to secrete more insulin by “working overtime”; they also enhance the binding of insulin to its receptors and relieve the effects of post-receptor insulin resistance, so that insulin action is enhanced, in order to increase insulin secretion and lower blood glucose. The purpose of lowering blood sugar by increasing insulin secretion. These drugs mainly include: glipizide, gliclazide, glibenclamide, glibenclamide, glipauride, glimepiride, and gliaquine. 2. Non-sulfonylurea benzoic acid derivative secretagogues, which are different from sulfonylureas in that they can enhance the body’s sensitivity to insulin, thus enabling the collective remaining normal islet cells to secrete more insulin by “replacing artificial with mechanical and improving efficiency This allows the collective remaining normal islet cells to secrete more insulin by “switching from artificial to mechanical, increasing the efficiency”. The main drugs in this category are: nateglinide and repaglinide. 3. Metformin, which is a drug that “promotes the absorption of glucose in other tissues”, “inhibits the conversion of other substances into glucose” and “slows down the absorption of glucose in the body”. These drugs directly reduce the “amount” of blood glucose by three ways: “promoting the absorption of glucose in other tissues”, “inhibiting the conversion of other substances into glucose”, and “slowing down the absorption of glucose in the body”, instead of stimulating insulin secretion by pancreatic cells after blood glucose rises. These drugs include metformin hydrochloride. 4. α-glucosidase inhibitors, which inhibit or slow down the process of converting various types of food into glucose in the body, i.e., the “negative idle” method. They are effective in lowering postprandial blood sugar. The company’s main business is to promote the development of a new product, which is a new product.
.